ArticleThe oncologist2026
Optimizing postoperative prognostication in duodenal adenocarcinoma: a multicenter study with external validation.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of adjuvant chemotherapy in small bowel adenocarcinomas.The oncologist · 2026Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
objectiveTo develop and externally validate a prognostic nomogram for overall survival (OS) in resected duodenal adenocarcinoma (DA) using routinely available perioperative variables, thereby clarifying risk profiles and supporting clinical management.
methodsMulticenter analysis of 2289 consecutive DA patients undergoing curative surgery (2012-2022) from China's National Cancer Center database. External validation used 335 patients from Zhejiang Provincial People's Hospital (2022-2024). LASSO-Cox regression selected variables from 89 perioperative factors to construct the nomogram, with web tool implementation.
resultsThe LASSO-Cox model achieved 1-, 3-, and 5-year AUCs of 0.72 (95% CI, 0.68-0.77), 0.75 (95% CI, 0.72-0.77), and 0.76 (95% CI, 0.73-0.79), outperforming traditional Cox models (P < .01). External validation yielded AUCs of 0.76 (95% CI, 0.66-0.86) and 0.79 (95% CI, 0.74-0.86) for 1- and 3-year OS, and 0.81 (95% CI, 0.74-0.89) for estimated 5-year OS. The model stratified patients into low- and high-risk groups (cutoff 0.40), with low-risk patients showing superior survival. Eight predictors were selected, including modifiable surgical factors such as transfusion and operative time.
conclusionsWe developed and externally validated a postoperative prognostic nomogram for DA using routinely available perioperative variables. In the present study, the model improved postoperative risk stratification and may support counseling, follow-up planning, and multidisciplinary discussion regarding adjuvant therapy; however, it should be viewed as complementary to standard staging and clinical judgment, and broader clinical implementation will require further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.